Related Experiment Video
Updated: Aug 5, 2025
Author Spotlight: Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue
Published on: May 26, 2023
Pancreatic Cancer Organoids: An Emerging Platform for Precision Medicine?
Evangelia Sereti1, Irida Papapostolou2, Konstantinos Dimas3
1Department of Translational Medicine, Lund University, 22363 Lund, Sweden.
Abstract:
Despite recent therapeutic advances, pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies, with remarkable resistance to treatment, poor prognosis, and poor clinical outcome. More efficient therapeutic approaches are urgently needed to improve patients' survival. Recently, the development of organoid culture systems has gained substantial attention as an emerging preclinical research model. PDAC organoids have been developed to study pancreatic cancer biology, progression, and treatment response, filling the translational gap between in vitro and in vivo models. Here, we review the rapidly evolving field of PDAC organoids and their potential as powerful preclinical tools that could pave the way towards precision medicine for pancreatic cancer.
Insights
Pancreatic cancer organoids offer a promising new model for studying this aggressive disease. These models help bridge the gap between lab research and patient treatment, advancing precision medicine for pancreatic ductal adenocarcinoma.
Area of Science:
- Oncology
- Biomedical Research
- Translational Medicine
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with limited treatment options and poor patient outcomes.
- Existing preclinical models struggle to accurately reflect human pancreatic cancer complexity, hindering therapeutic development.
- There is a critical need for improved models to accelerate the discovery of effective pancreatic cancer treatments.
Purpose of the Study:
- To review the current landscape and potential of pancreatic ductal adenocarcinoma (PDAC) organoids.
- To highlight the utility of PDAC organoids in understanding cancer biology and treatment response.
- To explore how PDAC organoids can facilitate the advancement of precision medicine in pancreatic cancer.
Main Methods:
- Review of recent literature on pancreatic ductal adenocarcinoma (PDAC) organoid development and application.
- Analysis of the role of organoids in preclinical cancer research.
- Discussion of the translational potential of organoid models in oncology.
Main Results:
- Organoid culture systems represent a significant advancement in preclinical cancer research.
- PDAC organoids effectively model key aspects of pancreatic cancer biology and progression.
- Organoids demonstrate utility in predicting treatment responses, bridging the in vitro-in vivo gap.
Conclusions:
- Pancreatic ductal adenocarcinoma (PDAC) organoids are powerful tools for advancing pancreatic cancer research.
- Organoid models hold significant promise for improving therapeutic strategies and patient outcomes.
- The application of PDAC organoids is crucial for the future of precision medicine in pancreatic cancer.
